financial estimates
Quanterix Counting on Multi-Marker Approach as Differentiator in Crowded Alzheimer's Dx Field
Premium
The company expects its five-marker LucentAD Complete test to offer higher performance than single-marker assay and to secure higher reimbursement.
Myriad Genetics Enters Collaborations to Study MRD, Announces Preliminary Q3 Revenue Estimates
The company is studying the use of its Precise MRD test in the breast cancer setting. It also said it estimates between $210 million and $212 million in Q3 revenue.
In Brief This Week: Danaher; Seegene; Mainz Biomed
News items for the week of Sept. 2, 2024.
MDxHealth Preliminary Q2 Revenues up 32 Percent
The company also raised its full-year 2024 guidance to up to $87 million, citing sales execution and operating discipline as drivers for its improved outlook.
QuidelOrtho Suspends Guidance After Lowering Full-Year Expectations on COVID, Savanna MDx Platform
Premium
The firm said it expects to reinstate guidance and reschedule its Investor Day at some point this year as new CEO Brian Blaser continues to assess the business.
May 3, 2024
Fulgent Genetics Core Q1 Revenues Grow 1 Percent
Apr 20, 2022